InvestorsHub Logo
Followers 47
Posts 12035
Boards Moderated 0
Alias Born 09/12/2017

Re: SF Anony post# 145516

Monday, 02/08/2021 5:52:48 PM

Monday, February 08, 2021 5:52:48 PM

Post# of 232880
So NP says "We had more serious adverse effects" then says "None of the SAEs in the leronlimab arm were deemed related to study drug administration by the investigators." correct?

So THIS is the truth too right?...for example---




CytoDyn Requests Covid-19 Emergency Use Approval For Leronlimab
Late-stage biotech CytoDyn Inc (CYDY) has announced that it has provided its Top-line Report from its recently completed Phase 2 trial of leronlimab for COVID-19 patients with mild-to-moderate symptoms to the U.S. Food and Drug Administration (FDA), and requested emergency use approval.


https://finance.yahoo.com/news/cytodyn-requests-covid-19-emergency-125739300.html

PATHETIC

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News